

# CONTENTS

---

Preface .....	vii
Contributors .....	xiii

## **PART I. PHYSIOLOGICAL RESISTANCE**

1 The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors <i>Mark W. Dewhirst, Yiting Cao, Benjamin Moeller, and Chuan-Yuan Li</i> .....	3
2 Influence of Tumor pH on Therapeutic Response <i>Chang W. Song, Robert Griffin, and Heon Joo Park</i> .....	21
3 Tumor Oxygenation and Treatment Response <i>Sarah Jane Lunt and Richard P. Hill</i> .....	43
4 Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance: <i>The Role of Evolving Interrelationships Between Cancer Cells and Host Tissues</i> <i>Janusz W. Rak, Brenda Coomber, and Joanne L. Yu</i> .....	67
5 PET Imaging of Response and Resistance to Cancer Therapy <i>David A. Mankoff and Kenneth A. Krohn</i> .....	105

## **PART II: BIOLOGICAL RESISTANCE**

6 Cancer Stem Cells: <i>Implications for Development of More Effective Therapies</i> <i>Ilia Mantle, Gabriela Dontu, Suling Liu, and Max S. Wicha</i> .....	125
7 Therapeutic Resistance in Leukemia <i>William R. Waud</i> .....	137
8 Tumor Site Implantation and Animal Model Selection in Oncology <i>Anibal A. Arjona and Enrique Alvarez</i> .....	151
9 In Vivo Resistance <i>Beverly A. Teicher</i> .....	161
10 Characteristics of the Metastatic Phenotype: <i>The Melanoma Experience</i> <i>Vladislava O. Melnikova and Menashe Bar-Eli</i> .....	181
11 The Microenvironment and Drug Resistance <i>Patrice J. Morin</i> .....	201

**PART III. BIOCHEMICAL RESISTANCE**

- 12 Glutathione and Glutathione *S*-Transferases in Drug Resistance  
*Victoria J. Findlay, Danyelle M. Townsend,  
and Kenneth D. Tew*..... 213
- 13 Metallothioneins in Drug Resistance  
*Faiyaz Notta and D. James Koropatnick* ..... 223
- 14 Molecular Determinants of Intrinsic Multidrug Resistance  
in Cancer Cells and Tumors  
*Elena Monti* ..... 241
- 15 New and Revised Concepts in Multidrug Resistance:  
*Sestamibi, SNPs, Substrates, and Stem Cells*  
*Susan E. Bates, John Deeken, Chaohong Fan,  
and Robert W. Robey* ..... 261
- 16 Cisplatin Resistance: *Molecular Basis of a Multifaceted Impediment*  
*Zahid H. Siddik*..... 283
- 17 Regulation of the Cellular Pharmacology and Cytotoxicity  
of Cisplatin by Copper Transporters  
*Roohangiz Safaei and Stephen B. Howell* ..... 309
- 18 Resistance to Taxanes  
*Lee M. Greenberger and Deepak Sampath*..... 329
- 19 CpG Island Methylation and Drug Resistance  
*Jens M. Teodoridis and Robert Brown* ..... 359
- 20 *De Novo* and Acquired Resistance to Antitumor Alkylating Agents  
*Lori A. Hazlehurst and William S. Dalton* ..... 377
- 21 Resistance to Antiangiogenic Agents  
*George W. Sledge, Jr., Kathy D. Miller, Bryan Schneider,  
and Christopher J. Sweeney* ..... 391

**PART IV. THE ROLE OF HORMONES, GROWTH FACTORS, AND ONCOGENES**

- 22 Resistance to Antiestrogens  
*Clodia Osipo and Ruth M. O'Regan* ..... 413
- 23 Mechanisms of Glucocorticoid Actions and Resistance  
in Multiple Myeloma  
*Varsha Gandhi and Beatriz Sanchez-Vega* ..... 435
- 24 Herceptin Resistance  
*Ingrid A. Mayer and Carlos L. Arteaga* ..... 459

---

25	Role of TGF- $\beta$ in Tumor Progression and Metastasis <i>Jan Pinkas and Beverly A. Teicher</i> .....	469
26	p53-Based Immunotherapy of Cancer <i>Albert B. DeLeo</i> .....	491
27	Response and Resistance to Ionizing Radiation <i>Paul Dent, Adly Yacoub, Michael P. Hagan, and Steven Grant</i> .....	507
28	Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance <i>M. Jim Yen, Ie-Ming Shih, Victor E. Velculescu, and Tian-Li Wang</i> .....	531
<b>PART V. CLINICAL ASPECTS OF RESISTANCE</b>		
29	Cancer Chemotherapy: <i>Clinical Evidence for Drug Resistance</i> <i>Mika A. Sovak and David R. Spriggs</i> .....	543
30	Molecular Profiling in Breast Cancer: <i>Genomic Approaches Toward Tailored Cancer Therapies</i> <i>Kristin Kee and Jeffrey E. Green</i> .....	559
31	Tumor Immune Escape Mechanisms <i>Yi Ting Koh, M. Luz García-Hernández, and W. Martin Kast</i> .....	577
	Index .....	603